Literature DB >> 10733746

Frequency of CCR5 delta-32 mutation in human immunodeficiency virus (HIV)-seropositive and HIV-exposed seronegative individuals and in general population of Medellin, Colombia.

F J Díaz1, J A Vega, P J Patiño, G Bedoya, J Nagles, C Villegas, R Vesga, M T Rugeles.   

Abstract

Repeated exposure to human immunodeficiency virus (HIV) does not always result in seroconversion. Modifications in coreceptors for HIV entrance to target cells are one of the factors that block the infection. We studied the frequency of Delta-32 mutation in ccr5 gene in Medellin, Colombia. Two hundred and eighteen individuals distributed in three different groups were analyzed for Delta-32 mutation in ccr5 gene by polymerase chain reaction (PCR): 29 HIV seropositive (SP), 39 exposed seronegative (ESN) and 150 individuals as a general population sample (GPS). The frequency of the Delta-32 mutant allele was 3.8% for ESN, 2.7% for GPS and 1.7% for SP. Only one homozygous mutant genotype (Delta-32/Delta-32) was found among the ESN (2.6%). The heterozygous genotype (ccr5/Delta-32) was found in eight GPS (5.3%), in one SP (3.4%) and in one ESN (2.6%). The differences in the allelic and genotypic frequencies among the three groups were not statistically significant. A comparison between the expected and the observed genotypic frequencies showed that these frequencies were significantly different for the ESN group, which indirectly suggests a protective effect of the mutant genotype (Delta-32/Delta-32). Since this mutant genotype explained the resistance of infection in only one of our ESN persons, different mechanisms of protection must be playing a more important role in this population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733746     DOI: 10.1590/s0074-02762000000200018

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  8 in total

1.  Identification and frequency of CCR5Δ32/Δ32 HIV-resistant cord blood units from Houston area hospitals.

Authors:  G Gonzalez; Ss Park; Dw Chen; S Armitage; Ej Shpall; Rr Behringer
Journal:  HIV Med       Date:  2011-03-06       Impact factor: 3.180

Review 2.  [Genetic susceptibility to infections].

Authors:  S J Ott; S Schreiber
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

3.  Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia.

Authors:  Wildeman Zapata; Wbeimar Aguilar-Jiménez; Nicolás Pineda-Trujillo; Winston Rojas; Hernando Estrada; María T Rugeles
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-09       Impact factor: 2.205

4.  Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals.

Authors:  Wildeman Zapata; Benigno Rodriguez; Jan Weber; Hernando Estrada; Miguel E Quiñones-Mateu; Peter A Zimermman; Michael M Lederman; Maria T Rugeles
Journal:  Curr HIV Res       Date:  2008-11       Impact factor: 1.581

5.  Analysis of the CCR5 gene coding region diversity in five South American populations reveals two new non-synonymous alleles in Amerindians and high CCR5*D32 frequency in Euro-Brazilians.

Authors:  Angelica B W Boldt; Lodércio Culpi; Luiza T Tsuneto; Ilíada R Souza; Jürgen F J Kun; Maria Luiza Petzl-Erler
Journal:  Genet Mol Biol       Date:  2009-01-16       Impact factor: 1.771

6.  Genetic and Immunological Factors Involved in Natural Resistance to HIV-1 Infection.

Authors:  Natalia Taborda-Vanegas; Wildeman Zapata; María Teresa Rugeles
Journal:  Open Virol J       Date:  2011-05-11

7.  Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis.

Authors:  Sijie Liu; Chuijin Kong; Jie Wu; Hao Ying; Huanzhang Zhu
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

8.  Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals.

Authors:  Enrico M Trecarichi; Mario Tumbarello; Katleen de Gaetano Donati; Enrica Tamburrini; Roberto Cauda; Christina Brahe; Francesco D Tiziano
Journal:  AIDS Res Ther       Date:  2006-09-25       Impact factor: 2.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.